82486
document
Efficacy and safety of timolol/pilocarpine combination drops in glaucoma patients . The aim of this randomized , double-blind study with two parallel groups was to examine the safety , efficacy and tolerability of two combination eye drops containing 0.5 % timolol and 2 % pilocarpine ( Fotil , Leiras , Finland , and Timpilo , MSD , USA ) in patients with glaucoma or ocular hypertension . Efficacy was determined based on daytime intraocular pressure curve and safety by examining visual fields , visual acuity , optic discs , by determining blood pressure and pulse rate , and by performing Schirmer and fluorescein tests . A total of 89 patients were enrolled , and 71 completed the 10-week treatment period . This study showed that the two combinations of 0.5 % timolol maleate and 2 % pilocarpine HCl compared in this study were equally effective in reducing intraocular pressure . The decrease in mean daily intraocular pressure from 0 to 10 weeks was 7.48 mmHg for Fotil , and 6.31 for Timpilo . The mean decrease in mean daily intraocular pressure was 29.3 % for Fotil , and 26.0 % for Timpilo . No significant differences were found between the groups . Adverse event were reported by 70 out of 89 patients by the end of 2 weeks , but were severe enough only in 11 for the treatment to be discontinued . In all others , adverse events were of transient nature and considered mild . In general , adverse events were similar in both study groups . However , burning was more common in patients on Fotil , and blurring of vision and light sensitivity were more common in patients on Timpilo . In patients with no contraindication to beta-blockers , these drugs appeared to be safe . ( ABSTRACT TRUNCATED AT 250 WORDS )
82487
Intervention_Pharmacological
timolol/pilocarpine
82488
Intervention_Pharmacological
timolol
82489
Intervention_Pharmacological
pilocarpine
82490
Intervention_Pharmacological
timolol maleate
82491
Intervention_Pharmacological
pilocarpine HCl
82492
Outcome_Physical
intraocular pressure
82493
Outcome_Physical
mean daily intraocular pressure
82494
Outcome_Physical
mean daily intraocular pressure
82495
Outcome_Adverse-effects
Adverse event
82496
Outcome_Adverse-effects
adverse events
82497
Outcome_Adverse-effects
adverse events
82498
Outcome_Physical
burning
82499
Outcome_Physical
blurring of vision and light sensitivity
82500
Participant_Condition
glaucoma patients .
82501
Participant_Condition
patients with glaucoma or ocular hypertension .
82502
Participant_Condition
total of 89 patients were enrolled , and 71 completed the 10-week treatment period .